S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024

Legend Biotech (LEGN) Stock Price, News & Analysis

$56.09
-0.84 (-1.48%)
(As of 03/28/2024 ET)
Today's Range
$55.00
$56.87
50-Day Range
$55.06
$69.99
52-Week Range
$44.52
$77.32
Volume
661,678 shs
Average Volume
1.08 million shs
Market Capitalization
$9.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$82.76

Legend Biotech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
47.5% Upside
$82.76 Price Target
Short Interest
Bearish
6.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.16mentions of Legend Biotech in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.39) to $0.12 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.66 out of 5 stars

Medical Sector

500th out of 939 stocks

Pharmaceutical Preparations Industry

241st out of 444 stocks

LEGN stock logo

About Legend Biotech Stock (NASDAQ:LEGN)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

LEGN Stock Price History

LEGN Stock News Headlines

Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Guru Fundamental Report for LEGN
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Company News for Mar 12, 2024
Legend Biotech Corporation Q4 Loss beats estimates
What 4 Analyst Ratings Have To Say About Legend Biotech
LEGN Jun 2024 100.000 put
LEGN Dec 2024 100.000 call
Legend Biotech Corp (LEGN)
Legend Biotech Corporation (LEGN)
See More Headlines
Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
3/28/2024
Next Earnings (Estimated)
5/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LEGN
Fax
N/A
Employees
1,390
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$82.76
High Stock Price Target
$94.00
Low Stock Price Target
$64.00
Potential Upside/Downside
+47.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$-518,250,000.00
Net Margins
-181.75%
Pretax Margin
-182.41%

Debt

Sales & Book Value

Annual Sales
$285.14 million
Book Value
$6.88 per share

Miscellaneous

Free Float
165,034,000
Market Cap
$9.26 billion
Optionable
Optionable
Beta
0.04
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Ying Huang Ph.D. (Age 51)
    CEO & Director
  • Mr. Doug Wallace
    Vice President of Global Operations
  • Dr. Guowei Fang Ph.D.
    Chief Scientific Officer & Head of Business Development
  • Joanne Choi
    Senior Manager of Investor Relations
  • Mr. James Pepin J.D.
    General Counsel
  • Deborah Wong
    Executive Director of Strategic Marketing & Corporate Communications
  • Ms. Elaine Qian
    VP & Global Head of Human Resources
  • Dr. Yuhong Qiu Ph.D.
    Senior Vice President of Global Regulatory Affairs
  • Mr. Steven J. Gavel
    Senior Vice President of Commercial Development, US & Europe
  • Mr. Alan Kick
    Senior Vice President of Global Quality

LEGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Legend Biotech stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LEGN shares.
View LEGN analyst ratings
or view top-rated stocks.

What is Legend Biotech's stock price target for 2024?

13 Wall Street research analysts have issued 1 year target prices for Legend Biotech's stock. Their LEGN share price targets range from $64.00 to $94.00. On average, they expect the company's stock price to reach $82.76 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price.
View analysts price targets for LEGN
or view top-rated stocks among Wall Street analysts.

How have LEGN shares performed in 2024?

Legend Biotech's stock was trading at $60.17 at the beginning of the year. Since then, LEGN stock has decreased by 6.8% and is now trading at $56.09.
View the best growth stocks for 2024 here
.

When is Legend Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024.
View our LEGN earnings forecast
.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) posted its quarterly earnings data on Monday, March, 11th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.70) by $0.30. The firm earned $76.50 million during the quarter, compared to the consensus estimate of $95.63 million. Legend Biotech had a negative net margin of 181.75% and a negative trailing twelve-month return on equity of 37.19%. The company's revenue for the quarter was up 177.2% compared to the same quarter last year.

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

When did Legend Biotech IPO?

Legend Biotech (LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO.

Who are Legend Biotech's major shareholders?

Legend Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (5.95%), Hhlr Advisors LTD. (3.29%), Capital World Investors (1.31%), Wellington Management Group LLP (1.27%), Massachusetts Financial Services Co. MA (1.09%) and Capital International Investors (1.00%).

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LEGN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners